Affinergy teams with Synthes
This article was originally published in The Gray Sheet
Executive Summary
"Biological glue" proprietor Affinergy and orthopedic device manker Synthes will collaborate on multiple product applications across the spine, trauma and craniomaxillofacial markets under a long-term development program announced Sept. 11. Affinergy's Interfacial Biomaterial coating process can reduce the risks of infection, friction and clotting associated with an orthopedic implant, and "provide for a much tighter integration of the actual device," the company says (1"The Gray Sheet" March 8, 2004, p. 26). The firm is interested in targeting the cardiovascular market as well...
You may also be interested in...
Affinergy Exploring BMP Applications For IFBM Device Coating Process
Affinergy's plan to license its Interfacial Biomaterial (IFBM) coating process will allow the start-up to avoid the costs of bringing a combination product to market
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.